Skip to content

Greater Trochanteric Pain Syndrome: Corticosteroid vs. Prolotherapy

Therapeutic Efficacy of Local Corticosteroid Injection versus Ultrasound-guided Prolotherapy in Greater Trochanteric Pain Syndrome

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151017024572N25
Enrollment
36
Registered
2024-09-07
Start date
2024-06-21
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Greater Trochanteric Pain Syndrome. Trochanteric bursitis, unspecified hip

Interventions

Intervention 1: Intervention group: In this group, corticosteroid injections will be administered under ultrasound guidance. The intervention involves the injection of 1 ml of 40 mg Triamcinolone Acet

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 40 Soft tissue swelling at the site of the greater trochanter Pain in the hip joint area (score above 5 according to the VAS scale) Tenderness at the greater trochanter site upon palpation Ultrasound evidence of increased synovial thickness and fluid accumulation in the greater trochanter bursa Ultrasound evidence of inflammation in the tendons surrounding the greater trochanter

Exclusion criteria

Exclusion criteria: Concurrent rheumatologic diseases Presence of calcification at the site of corticosteroid/prolotherapy injection Presence of skin infection at the site of corticosteroid/prolotherapy injection History of drug injection or physical therapy at the intervention site within the past two months Positive history of coagulative disorders Positive history of lumbosacral radiculopathy

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale. Timepoint: Before and after treatment (1 week, 2 months, 6 months). Method of measurement: The visual scale is shown to the patient, and they are asked to rate the intensity of the pain they are experiencing from 0 to 10.

Secondary

MeasureTime frame
Range of Motion (ROM). Timepoint: Before and after treatment (1 week, 2 months). Method of measurement: The hip joint's range of motion is measured using a goniometer. For this purpose, the patient performs internal rotation, external rotation, adduction, and abduction maneuvers, and the evaluator measures the joint's range of motion while the patient is lying down.;Short Form (36) Health Survey Score. Timepoint: Before and after treatment (1 week, 2 months). Method of measurement: The SF-36 is a health-related quality of life questionnaire introduced in 1992. It contains 36 questions, with responses varying across different dimensions, though most are on a Likert scale. This questionnaire covers eight dimensions: physical functioning (10 questions), role limitations due to physical health (4 questions), role limitations due to emotional problems (3 questions), energy and vitality (4 questions), emotional well-being (5 questions), social functioning (2 questions), pain (3 questions), and general health (5 questions). The lowest score on this questionnaire is 0, and the highest score is 100.;Harris Hip Score (HHS). Timepoint: Before and after treatment (1 week, 2 months). Method of measurement: The Harris Hip Score is a quantitative scale used to assess the level of disability in the hip joint. It consists of 12 items divided into four sections: pain severity (1 item, score 0 to 44), function (7 items, score 0 to 47), absence of deformity (1 item, score 0 to 4), and range of motion (2 items, score 0 to 5). In this scale, a total score of 0 indicates the highest level of disability, while a score of 100 indicates the least disability.;Clinical Global Impression (CGI). Timepoint: Before and after treatment (1 week, 2 months). Method of measurement: The CGI is comprised of two accompanying measures that assess the following: (a) the severity of psychopathology on a scale of 1 to 7, and (b) change from the start of treatment on a similar seven-point scale. After clinical

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Babaei-Ghazani

Iran University of Medical Sciences

babaei-ghazani.a@iums.ac.ir+98 21 6435 2683

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026